Pfizer’s Outlook Improves

Pfizer’s Outlook Improves
Having spent $5 billion on research and development in 2002, Pfizer (NYSE: PFE) is king of the drug world. And with its $60 billion Pharmacia merger completed in April, the king just got fatter


Leave a Reply

Your email address will not be published. Required fields are marked *

Get email updates

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Subscribe!